ABOUT US THE SCIENCE PIPELINE NEWS CONTACT INVESTORS About Us HCW Biologics is developing transformative immunotherapies to lengthen healthspan by disrupting inflammaging. HCW Biologics is an innovative immunotherapy company developing novel therapeutics designed to disrupt the link between chronic, low-grade inflammation and age-related disorders. This field, known as inflammaging, targets the unresolved inflammatory responses and chronic, low-grade inflammation associated with advancing age and believed to be a significant contributing factor to cancer and several chronic conditions, including cardiovascular disease, diabetes, neurodegenerative disease, and autoimmune disease. The core of HCW’s discovery and development efforts revolves around the company’s internally developed Tissue FactOr-Based FusIon (TOBI™) platform, which is designed to engineer multi-functional fusion protein molecules and protein complexes. The technology employs a Tissue Factor (TF) scaffold that can be packaged with multiple protein targets, including cytokines, chemokines, ligands, receptors, and single-chain antibodies, carefully selected to work in tandem to stimulate and target desired immune responses and inhibit unwanted inflammation. About Us Leadership and Board The Science TOBI™ Platform Our Focus Pipeline News News Releases Publications Contact General Inquiries Careers Investors Copyright © 2021 HCW Biologics Inc.

Skip to main navigation INVESTOR RELATIONS Corporate Profile HCW Biologics is developing transformative immunotherapies to lengthen healthspan by disrupting inflammaging. HCW Biologics is an innovative immunotherapy company developing novel therapeutics designed to disrupt the link between chronic, low-grade inflammation and age-related disorders. This field, known as inflammaging, targets the unresolved inflammatory responses and chronic, low-grade inflammation associated with advancing age and believed to be a significant contributing factor to cancer and several chronic conditions, including cardiovascular disease, diabetes, neurodegenerative disease, and autoimmune disease. HCW Biologics Inc.(NasdaqGM:HCWB) added to S&P TMI Index Data Provided by Refinitiv. Minimum 15 minutes delayed. > View All Stock ANALYST COVERAGE STOCK CHARTS News Releases NOV 12, 2021 HCW Biologics Reports Third Quarter Financial Results and Recent Business Highlights OCT 28, 2021 HCW Biologics Receives FDA Clearance to Proceed with Phase 1b Clinical Trial for Immunotherapeutic HCW9218 for Pancreatic Cancer OCT 27, 2021 HCW Biologics Announces Appointment of Two New Members to Board of Directors > View All News VIEW ALL Events & Presentations NOV 19, 2021 EF Hutton Initiates Coverage on HCW Biologics with Buy Rating OCT 28, 2021 Corporate Presentation OCT 28, 2021 HCW Biologics shares leap higher on pancreatic cancer program progress - BioWorld > View All Events VIEW ALL SEC Filings DEC 03, 2021 Statement of changes in beneficial ownership of securities 4 > View All SEC VIEW ALL > Investor Tools Print Page Email Alerts RSS Feeds © HCW Biologics, Inc. 2021